Spectrum Of Activity
Usual doseBacterial meningitisMSSA infection1-2 g IV #1-22 g IV q12h (max 4 g/d)2-4 g IV #1-2No renal dose adjustment
SSTISevere non-CNS infectionBacterial meningitis50-75 mg/kg IV #1-2 (max 2 g/d)50-75 mg/kg IV #2 (max 2 g/d)100 mg/kg IV #1-2 (max 4 g/d)No renal dose adjustment
No dose adjustment
Empiric therapy of:
Nosocomial gram negative infections (except Pseudomonas)
Spontaneous bacterial peritonitis
Hospitalized community or nursing home-acquired pneumonia in combination with a macrolide
Monitor CBC, hepatic and renal functions, previous hypersensitivity to other beta-lactam antibiotics, and signs of antibiotic-associated diarrhea and other superinfections.
Injection site induration
Toxic epidermal necrolysis
Clostridium difficile colitis
Injury of lung
Lactated Ringer's solution
Calcium-containing IV solutions
Major drug-drug interactions:
- Cholera vaccine, live
Antimicrobial class: 3rd Generation Parenteral Cephalosporin
Pregnancy category: B
Average serum half life: 8 hours
Biliary penetration: Therapeutic
CSF penetration: Therapeutic
Lung penetration: Therapeutic
Urine penetration: Therapeutic
Do not concurrently administer calcium-containing IV solutions in same IV line, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site; may be administered sequentially in patients other than neonates with thorough flushing of lines with compatible fluid between administrations.
Increased risk of drug toxicity in renal failure.
Use caution in patients with impaired vitamin K synthesis or low vitamin K stores due to risk of rare prothrombin time alteration.
Discontinue if hemolytic anemia occurs.
Use caution in patients with history of allergy.